Abstract:During the past decade, epigenetic control of cardiac remodeling has attracted attention as a major mechanism contributing to heart failure. The BET family of bromodomain proteins (BRD) functions as “readers” of acetylated chromatin. Pharmacological inhibition of BRD proteins prevents cardiac hypertrophy and heart failure in preclinical models, yet mechanistic studies elucidating the biology of BRD proteins in the heart are lacking. Here, we investigated the role(s) of BRD4 in cardiac physiology and pathophysiology. By engineering a cardiomyocyte-specific BRD4 knockout mouse, we discovered that loss of BRD4 triggered progressive decline in ventricular contractile function, culminating in dilated cardiomyopathy in both post-natal and adult hearts. To identify early transcriptomic changes in BRD4-ablated heart, we conducted a global transcriptome analysis in KO hearts prior to the onset of ventricular dysfunction. RNA sequencing analysis of BRD4 KO hearts revealed disruption of genes essential to mitochondrial energy production and homeostasis, as well as key cardiac sarcomeric components. Computational analysis identified key transcription factors involved in BRD4-mediated gene regulation, including MEF2 complex, ERR1, SRF, and Nkx2.5. By studying isolated cardiomyocytes maintained in primary culture, we confirmed that disruption of the candidate TF complexes by BRD4 ablation altered mitochondrial morphology and provoked progressive contractile dysfunction. In aggregate, we describe for the first time a critical role of BRD4 in regulating key cardiomyocyte gene networks, in particular genes involved in mitochondrial homeostasis and contractility, to maintain cardiac function. Moreover, our data suggest that BRD4 is a novel regulator of epigenetic events in dilated cardiomyopathy. Elucidating these novel roles of BRD4 in cardiomyocyte remodeling will provide critical insights into the epigenetic control of stress-related cardiac events with potential clinical relevance.

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis

The epigenetic reader Brd4 is required for osteoblast differentiation

BRD2 Interconnects with BRD3 to Facilitate Pol II Transcription Initiation and Elongation to Prime Promoters for Cell Differentiation.

Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function.

Selective inhibition of BET bromodomains

KDM5C-mediated recruitment of BRD4 to chromatin regulates enhancer activation and BET inhibitor sensitivity

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth*

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell

BET Bromodomain Protein 4 (BRD4) Governance of Cardiovascular Disease Stress-related Cardiomyocyte Remodeling

Data from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

The Functions of BET Proteins in Gene Transcription of Biology and Diseases

Epigenetic Reader BRD4 Governs Nucleus-encoded Mitochondrial Transcriptome to Regulate Cardiac Function

Drug Discovery Targeting Bromodomain-Containing Protein 4

BRD4 Interacts with GATA4 to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes

A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT

Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy Via Regulating the Expression of Citrate Cycle Genes.

33-OR: Epigenetic Reader BRD4 Directs Fast-Twitch Myofiber Gene Programs Influencing Skeletal Muscle Endurance Capacity and Systemic Glucose Homeostasis

Small-molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential.